Updated from 2:15 p.m. EDT

Shares of eResearch Technology ( ERES) were among the worst-performing health and pharmaceutical stocks Thursday, falling 16.4% after the company posted third-quarter earnings that fell below Wall Street expectations and warned that fourth-quarter earnings and sales would be below expectations as well.

The supplier of technology used by biotech companies earned 13 cents a share during the third quarter on sales of $28 million. Analysts polled by Thomson First Call were expecting earnings of 14 cents a share on sales of $27.3 million. Looking ahead, eResearch forecast a fourth-quarter profit of 11 cents to 15 cents a share on sales of $26 million to $30 million. Analysts had been expecting earnings of 16 cents a share on sales of $31.5 million. Shares traded down $2.23 to $11.36.

Align Technology ( ALGN) fell 33.2% after the company delivered in-line third-quarter earnings results but turned in weaker-than-expected sales results. The maker of teeth-straightening products posted pro forma earnings of 7 cents a share on sales of $45.8 million. Analysts were expecting earnings of 7 cents a share on sales of $47.3 million. A year ago, Align earned 2 cents a share on sales of $34 million. Shares of Align traded down $4.92 to $9.90.

Shares of Apria Healthcare ( AHG) fell 4.3% after the company posted mixed third-quarter financial results and lowered its full-year earnings growth projections. The home health care company earned 60 cents a share during the third quarter on sales of $364.6 million. Analysts were expecting earnings of 59 cents a share on sales of $366.5 million. Looking ahead, Apria said that it believes it will turn in full-year earnings growth of 6% to 8%. Previously, the company said that it would grow earnings by 7% to 9%. Shares traded down $1.25 to $27.90.

Genaissance Pharmaceuticals ( GNSC) fell 12.6% after the company lowered its full-year sales guidance. The pharmaceutical company now expects sales of $20 million to $21 million, down from its previous guidance of $25 million. On a pro forma basis, the company now expects sales of $22 million to $23 million, which is down from previous guidance of $27 million. An analyst following the company had expected sales of $25 million. Genaissance said that its revised guidance is due to a shift in the timing of certain contracts. Shares traded down 35 cents to $2.43.

Other health care volume movers included Pfizer ( PFE), up 14 cents to $28.44; Amgen ( AMGN), down $2.13 to $54.28; StemCells ( STEM), up 30 cents to $2.84; Eli Lilly ( LLY), down $2.46 to $52.64; and Merck ( MRK), down 14 cents to $31.26.

More from Stocks

Lee Munson on the Market, Trade and the Possibility of a Recession

Lee Munson on the Market, Trade and the Possibility of a Recession

Buy These 3 Killer Tech Stocks, Says Wall Street's #1 Analyst

Buy These 3 Killer Tech Stocks, Says Wall Street's #1 Analyst

How Tariffs Can Impact the U.S. and the Global Capital Markets

How Tariffs Can Impact the U.S. and the Global Capital Markets

Here's Why Alphabet, Facebook and Amazon Earnings May Overshadow Tariff Worries

Here's Why Alphabet, Facebook and Amazon Earnings May Overshadow Tariff Worries

Trump's Attack on the Federal Reserve and China Leaves Investors Feeling Strange

Trump's Attack on the Federal Reserve and China Leaves Investors Feeling Strange